Immune-Onc Therapeutics

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, founded in 2016 by Charlene Liao and Guo Liang Yu. The company develops novel antibody therapeutics that target myeloid cell inhibitory receptors — with a current focus on the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) — to treat blood cancers, solid tumors, and autoimmune and inflammatory disease. Its clinical pipeline includes IO-108, a fully human IgG4 antagonist antibody targeting LILRB2 (ILT4) in Phase 1b/2 for solid tumors including hepatocellular carcinoma, and IO-202, a first-in-class IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute myeloid leukemia and chronic myelomonocytic leukemia, which holds FDA Fast Track and Orphan Drug designations. Preclinical programs include IO-312, a LILRB4-directed bispecific antibody, and IO-106 targeting LAIR1. The company has clinical collaborations with BeiGene, Regeneron, and Roche, and has raised approximately $138 million across Series A and Series B financings from investors including Northern Light Venture Capital, Vivo Capital, CLI Ventures, and the Stanford-StartX Fund. Immune-Onc is a therapeutics developer, not a software or platform company: as of this profile it publishes no public API, developer portal, OpenAPI or other machine-readable contract, no SDKs, no public GitHub organization and no /.well-known/ discovery surface — its only machine-readable documents are two Squarespace RSS feeds for its news and press-release collections. This record therefore captures the company's verified public identity, its published web properties, its clinical-trial registry presence, and the probed security posture of its public web surface.

Immune-Onc Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Oncology, and Immunotherapy.

Immune-Onc Therapeutics’ developer surface includes product news, engineering blog, and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyBiopharmaceuticalOncologyImmunotherapyImmuno-OncologyAntibodiesClinical TrialsLife SciencesHealthcareDrug Development

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 6.4/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/immune-onc-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Get Started 1

Portal, sign-up, and the first successful call

ClinicalTrials

ClinicalTrials

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

PressReleases

PressReleases

Company 7

The organization behind the API

Website

News

Blog

BlogRSS

BlogRSS

Careers

LinkedIn

Scroll for all 7

Other 6

Properties that don't map to a standard resource type

Team

Pipeline

Publications

ForPatients

ExpandedAccessPolicy

ExpandedAccessPolicy

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: immune-onc-therapeutics
name: Immune-Onc Therapeutics
description: 'Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California,
  founded in 2016 by Charlene Liao and Guo Liang Yu. The company develops novel antibody therapeutics that target myeloid
  cell inhibitory receptors — with a current focus on the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) — to
  treat blood cancers, solid tumors, and autoimmune and inflammatory disease. Its clinical pipeline includes IO-108, a fully
  human IgG4 antagonist antibody targeting LILRB2 (ILT4) in Phase 1b/2 for solid tumors including hepatocellular carcinoma,
  and IO-202, a first-in-class IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute myeloid leukemia and chronic myelomonocytic
  leukemia, which holds FDA Fast Track and Orphan Drug designations. Preclinical programs include IO-312, a LILRB4-directed
  bispecific antibody, and IO-106 targeting LAIR1. The company has clinical collaborations with BeiGene, Regeneron, and Roche,
  and has raised approximately $138 million across Series A and Series B financings from investors including Northern Light
  Venture Capital, Vivo Capital, CLI Ventures, and the Stanford-StartX Fund. Immune-Onc is a therapeutics developer, not a
  software or platform company: as of this profile it publishes no public API, developer portal, OpenAPI or other machine-readable
  contract, no SDKs, no public GitHub organization and no /.well-known/ discovery surface — its only machine-readable documents
  are two Squarespace RSS feeds for its news and press-release collections. This record therefore captures the company''s
  verified public identity, its published web properties, its clinical-trial registry presence, and the probed security posture
  of its public web surface.'
url: https://raw.githubusercontent.com/api-evangelist/immune-onc-therapeutics/refs/heads/main/apis.yml
image: https://static1.squarespace.com/static/60dc8b9325bba74a54bb572f/t/61003c309aa7560407b4842f/1627405360143/Imune-Onc%2BTheraputics_Logo%2BIteration_Final4-03.png?format=1500w
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-08-04'
  method: derived
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Oncology
- Immunotherapy
- Immuno-Oncology
- Antibodies
- Clinical Trials
- Life Sciences
- Healthcare
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/immune-onc-therapeutics-domain-security.yml
- type: WellKnown
  url: well-known/immune-onc-therapeutics-well-known.yml
- type: LLMsTxt
  url: llms/immune-onc-therapeutics-llms.txt
- type: Website
  url: https://www.immune-onc.com/
- type: Team
  url: https://www.immune-onc.com/team
- type: Pipeline
  url: https://www.immune-onc.com/pipeline
- type: Publications
  url: https://www.immune-onc.com/publications-abstracts
- type: PressReleases
  url: https://www.immune-onc.com/press-releases
- type: News
  url: https://www.immune-onc.com/news
- type: Blog
  url: https://www.immune-onc.com/news-1
- type: BlogRSS
  url: https://www.immune-onc.com/news-1?format=rss
- type: BlogRSS
  url: https://www.immune-onc.com/pr-posts?format=rss
- type: Careers
  url: https://www.immune-onc.com/careers
- type: ForPatients
  url: https://www.immune-onc.com/for-patients
- type: ExpandedAccessPolicy
  url: https://www.immune-onc.com/expanded-access-policy
- type: ClinicalTrials
  url: https://clinicaltrials.gov/search?spons=Immune-Onc%20Therapeutics
- type: LinkedIn
  url: https://www.linkedin.com/company/immune-onc-therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/immune-onc-therapeutics_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 1
  pass: local-v1